综述文章:炎症性肠病随机对照试验——常见挑战与潜在解决方案
该综述指出克罗恩病和溃疡性结肠炎临床试验的招募率逐年下降,通过检索文献、监管指南和会议资料并提取Trialtrove数据库中1989至2020年的试验数据,识别了影响招募的关键因素,并从以患者为中心的设计、减少安慰剂暴露、非侵入性终点和减轻行政负担等方面提出潜在解决方案。
要点
- 克罗恩病和溃疡性结肠炎临床试验的招募率每年持续下降,影响患者获得新疗法。
- 可探索平台试验等设计以减少安慰剂暴露,并继续研究非侵入性影像、生物标志物和新型数字终点。
- 使用电子签名等措施减轻试验行政负担,可能使研究中心和研究者受益。
核心结论
- 为改善克罗恩病和溃疡性结肠炎试验的招募,炎症性肠病学界应解决与临床试验实施相关的广泛问题。
研究设计与样本
- 综述文章,通过PubMed和Google检索炎症性肠病临床试验相关文献、监管指南和会议资料,并从Trialtrove数据库提取1989年至2020年间开展的炎症性肠病临床试验数据。
主要发现
- 克罗恩病和溃疡性结肠炎临床试验的招募率每年持续下降。
- 无法达到招募目标和完成试验对炎症性肠病界的利益相关者有严重影响。
- 识别了可能提高招募率的关键方面,包括改善关键试验文件的可读性、在试验规划中纳入患者代表、探索平台试验以减少安慰剂暴露、继续研究非侵入性影像、生物标志物和新型数字终点、使用电子签名减轻行政负担。
- COVID-19大流行期间对炎症性肠病试验所做的改变提供了试验实施可快速且建设性调整的示例。
临床怎么用
- 应采取日益以患者为中心的研究设计方法,包括改善关键试验文件的可读性并在试验规划中纳入患者代表。
- 安慰剂对患者缺乏吸引力,应探索包括平台试验在内的多种方法以尽量减少安慰剂暴露。
- 应继续研究非侵入性影像、生物标志物和新型数字终点以减少患者负担。
- 通过使用电子签名等方式减少与试验相关的行政负担,可能使研究中心和研究者受益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recruitment rates for Crohn's disease and ulcerative colitis clinical trials continue to decrease annually. The inability to reach recruitment targets and complete trials has serious implications for stakeholders in the inflammatory bowel disease (IBD) community. Action is required to ensure patients with an unmet medical need have access to new therapies to improve the management of their IBD. AIMS: Identify challenges contributing to recruitment decline in IBD clinical trials and propose potential solutions. METHODS: PubMed and Google were used to identify literature, regulatory guidelines and conference proceedings related to IBD clinical trials and related concepts. Data on IBD clinical trials conducted between 1989 and 2020 were extracted from the Trialtrove database. RESULTS: Key aspects that may improve recruitment rates were identified. An increasingly patient-centric approach should be taken to study design including improvements to the readability of key trial documentation and inclusion of patient representatives in trial planning. Placebo is unappealing to patients; approaches including platform trials should be explored to minimise placebo exposure. Non-invasive imaging, biomarkers and novel digital endpoints should continue to be examined to reduce the burden on patients. Reducing the administrative burden associated with trials via the use of electronic signatures, for example, may benefit study sites and investigators. Changes implemented to IBD trials during the COVID-19 pandemic provided examples of how trial conduct can be rapidly and constructively adapted. CONCLUSIONS: To improve recruitment in Crohn's disease and ulcerative colitis trials, the IBD community should address a broad range of issues related to clinical trial conduct.
引用
- Schreiber S, Irving PM, Sharara AI, et al. Review article: randomised controlled trials in inflammatory bowel disease-common challenges and potential solutions. Aliment Pharmacol Ther. 2022. PMID: 35132657. doi:10.1111/apt.16781
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。